FEB 2 6 2004

PTO/SB/21 (01-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. RADEMA Application Number 10/634,431 TRANSMITTAL Filing Date August 5, 2003 **FORM** First Named Inventor Guba Art Unit 1614 (to be used for all correspondence after initial filing) **Examiner Name** Attorney Docket Number 21152 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) to Group Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to Group Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer Extension of Time Request Identify below): Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority PTO Form 1449 with Reference (1), Statement Under 37 CFR Section 1.97(e), Search Report Document(s) and Post card. Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Eileen M. Ebel Individual Signature Date February 23, 2004 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class

mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date February 23, 2004 Typed or printed Eileen M. Ebel Date February 23, 2004 Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT APPLICATION



IE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors: Guba, et al

Group: 1614

Serial No. 10/634,431, filed: August 5, 2003

Examiner:

For: AMINOTHIAZOLE DERIVATIVES

STATEMENT UNDER 37 CFR §1.97(e)

Nutley, New Jersey 07110 Date: February 23, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify:

X That each item of information contained in the enclosed supplemental information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this supplemental information disclosure statement.

That <u>no</u> item of information contained in the supplemental information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

Attorney for Applicant(s)

Eileen M. Ebel (Reg. No. 37316) 340 Kingsland Street

Nutley, NJ 07110

Telephone: (973) 235-4391 Telefax: (973) 235-2363

PATENT APPLICATION



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s): Guba, et al.

Group: 1614

Serial No. 10/634,431, filed: August 5, 2003

Examiner:

For: AMINOTHIAZOLE DERIVATIVES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 Date: February 23, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Document B15 listed on Form PTO-1449 is enclosed.

Enclosed is a Search Report, dated November 27, 2003, which was issued by the European International Searching Authority in the corresponding PCT application. The Search Report lists Documents B8, B9 and B15. B8 and B9 are not enclosed since they have previously been submitted along with Applicant's Information Disclosure Statement mailed October 30, 2003.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/634,431

Filed: August 5, 2003

Because each item of information contained in the Supplemental Information Disclosure Statement was cited in a communication for the first time from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Supplemental Information Disclosure Statement, no fee is due. A Certification is enclosed.

Respectfully submitted,

Attorney for Applicant(s)

Eileen M. Ebel (Reg. No. 37316) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-4391 Telefax: (973) 235-2363

137479

_			for form 1449A/PTO	Complete if Known			
6E	JC708NFORMA	TION	DISCLOSURE	Application Number	10/634,431		
``	STEMI	ENT B	SY APPLICANT	Filing Date	August 5, 2003		
,	E Jan H			First Name Inventor	Guba		
.0	Use sev	RMATION DISCLOSURE EMENT BY APPLICANT se several sheets if necessary)	Group Art Unit	1614			
60	3			Examiner Name			
STEN	Sheet of	of	1	Attorney Docket Number	21152		
	K	-	USP	ATENT DOCUMENTS			

SHEET OF		01	<u> </u>		Attorney Docket Number 2	1132		
LAU				U.S. PATE	NT DOCUMENTS			
Examiner Initials'	Cite No.¹	U.S. Patent Document Kind Code² Number (if known)		ment Kind Code ²	Name of Patentee or Applicant of Cited Document		Date of Publication of Cited document MM-DD-YYYY	
				DEIGN DAG	TENT DOCUMENTS			
					TENT DOCUMENTS			
Examiner Initials'	Cite No.¹	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)			Name of Patentee or Applicant of Cited Document	0	Date of Publication of Cited Document MM-DD-YYYY	
	B15	WO 99 21845		(Agouron Pharma	05-06-1999		
			N-02					
						_		
Examiner Signature		Date Co	nsidered					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

To the communication of applicant.

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation or abstract is attached.